Table I.
Baseline patient characteristics
| Sotatercept dose group |
||||
|---|---|---|---|---|
| Parameter | Placebo (n = 6) | 0·1 mg/kg (n = 8) | 0·3 mg/kg (n = 8) | 0·5 mg/kg (n = 8) |
| Female, n (%) | 4 (66·7) | 2 (25·0) | 5 (62·5) | 4 (50·0) |
| Median age, years (range) | 63 (50–71) | 61 (43–79) | 64·5 (51–72) | 57·5 (41–78) |
| Median time since MM diagnosis, years (range) | 0·8 (0·2–2·2) | 3·8 (0·2–12·9) | 3·8 (0·6–18·0) | 1 (0–3·7) |
| Durie-Salmon stage at screening, n (%) | ||||
| II | 0 | 2 (25·0) | 2 (25·0) | 1 (12·5) |
| III | 6 (100) | 6 (75·0) | 6 (75·0) | 7 (87·5) |
| ECOG PS score, n (%) | ||||
| 0 | 2 (33·3) | 2 (25·0) | 3 (37·5) | 1 (12·5) |
| 1 | 3 (50·0) | 4 (50·0) | 5 (62·5) | 6 (75·0) |
| 2 | 1 (16·7) | 2 (25·0) | 0 | 1 (12·5) |
| Median haemoglobin, g/l (range) | 116 (93–141) | 119 (93–132) | 113 (89–136) | 114 (96–134) |
| Bisphosphonates,* n (%) | 3 (50·0) | 4 (50·0) | 2 (25·0) | 4 (50·0) |
| Prior radiotherapy, n (%) | 2 (33·3) | 1 (12·5) | 0 | 1 (12·5) |
| Prior chemotherapy, n (%) | 6 (100) | 8 (100) | 8 (100) | 6 (75·0) |
| Prior melphalan, n (%) | 6 (100) | 6 (75·0) | 6 (75·0) | 4 (50·0) |
| Prior thalidomide, n (%) | 0 | 1 (12·5) | 0 | 0 |
ECOG PS, Eastern Cooperative Oncology Group performance status; MM, multiple myeloma.
*
Bisphosphonates used concomitantly during the study.